{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fnew-data-on-covid-19-_7N6C0BC","width":444,"version":"1.0","type":"rich","title":"First-Generation TRK Inhibitors: Clinical Evidence and Indications","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/0a693064-1867-462e-8775-c78b3828e4e0/ntrk-podcast-am-podcasticon.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/d0d49c1a-d7d7-45b2-af29-82868e6d64d2\" height=\"200\" width=\"100%\" title=\"First-Generation TRK Inhibitors: Clinical Evidence and Indications\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"In this podcast episode, listen to an engaging discussion between George D. Demetri, MD, and Alexander Drilon, MD, on key clinical trials leading to FDA approvals of first-generation TRK inhibitors, where these agents fit into treatment paradigms for various solid tumors, and considerations for choosing among currently available TRK inhibitors."}